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Polymeric nanocarriers improve cellular uptake, stability, solubility, and functionality of 
entrapped drugs and nutraceuticals. The hypothesis of this study was that entrapping 
lutein, a hydrophobic antioxidant, in different polymeric nanoparticles (NPs) will 
improve its stability and antioxidant activity. The following objectives were proposed: 1. 
Synthesize and characterize polymeric nanoparticles of poly lactic co-glycolic acid 
(PLGA) and PLGA NPs covered with a layer of chitosan (PLGA/Chi) from a 
physicochemical perspective, and 2. Assess functionality of the entrapped lutein as a 
function of type of polymer in which entrapped. Nanoparticles were synthesized by 
emulsion evaporation method. Characterization included size, zeta potential, and 
morphology measurement, followed by testing the physical and chemical stability, and 
antioxidant activity of entrapped lutein. PLGA NPs loaded with lutein were in the size 
range of 119.2 nm ± 0.98 nm with a PDI of 0.17± 0.02  and a zeta potential of – 29 mV ± 
1.1 mV in nanopure water with 0.05 mg PVA/ mg PLGA ±  0.002 mg PVA/ mg PLGA 
remaining on the surface of the nanoparticles. PLGA/Chi NPs loaded with lutein were in 
the size range of 145.9 ± 0.3 nm with a PDI of 0.25 ± 00.01 and a zeta potential of 21.2 
mV ± 2.3 mV with 0.06 mg ±  0.002 mg PVA/ mg PLGA/Chi remaining in nanopure 
water. PLGA NPs and PLGA/Chitosan NPs loaded with lutein were stable in emulsions 
made with Tween 20 for 72 hours at 37 °C as indicated by a constant size over time. 
PLGA and PLGA/Chi NPs protected the chemical stability of lutein in Tween 20 
emulsions for 24 hours at 37 °C.  PLGA and PLGA/Chitosan NPs showed significant 
reductions in the oxidation of cholesterol by 45 ± 1% and 60 ± 1 % at 48 hours, and 36 ± 
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1 % and 42 ± 3 % at 72 hours when compared to the free lutein. The addition of chitosan 
to the PLGA NPs further enhanced the efficacy of lutein as an antioxidant when 
compared to PLGA NPs. These results support the hypothesis that polymeric NPs are 
enhancing stability and antioxidant activity of entrapped lutein and hence may find 
beneficial applications in the biomedical and food science fields for delivery of lutein.  
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CHAPTER 1: INTRODUCTION 
 
Antioxidants protect carbohydrates, proteins, nucleic acids and lipids from 
oxidation, for improved overall health of the consumer. Reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) cause oxidation of carbohydrates, proteins, and other 
molecules which is associated with diseases such as cardiovascular and inflammatory 
diseases, cancer, and premature aging. Mechanisms of oxidation occur through altering 
the chemical structure of lipids and other molecules inside the body. Natural defenses in 
the human body are designed to combat this oxidation; these defenses include natural 
antioxidants such as glutathione, bilirubin, α-tocopherol, and many others (Laguerre, 
Lecomte et al. 2007). However, the human body does not contain enough of these natural 
antioxidants to maintain a balance sufficient to diminish all oxidative stress (Laguerre, 
Lecomte et al. 2007). Therefore dietary antioxidants are necessary for protection against 
diseases and inflammation. Common exogenic dietary antioxidants include tocopherols, 
tocotrienols, flavonoids, and carotenoids (Laguerre, Lecomte et al. 2007).  
Many of these dietary antioxidants such as carotenoids and tocopherols are lipid 
soluble, which results in low bioavailability in vivo (Anand, Nair et al. 2010). These 
molecules are often photosensitive and easily oxidized leading to a further decrease in 
bioavailability and in vivo activity of these molecules (Canene-Adams and Erdman 
2009). A well-investigated solution for enhanced stability and bioavailability is the use of 
antioxidant nanoparticles as delivery systems (Choi, Zuckerman et al. 2011), (Faraji and 
Wipf 2009).  
In particular, polymeric nanoparticles made of polymers such as poly (lactic-co-
glycolic) acid (PLGA), poly-lactic acid (PLA), polyethylene glycol (PEG), zein, and low 
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molecular weight chitosan (LMWC) have shown to improve the bioavailability of various 
hydrophobic drugs and nutraceuticals (Arunkumar, Harish Prashanth et al. 2013), 
(Kumari, Yadav et al. 2010), (Anand, Nair et al. 2010), (Hu, Lin et al. 2012), (Hu, Liu et 
al. 2011) and provide protection from degradation of multiple photosensitive and unstable 
antioxidants (Trombino, Cassano et al. 2009), (Konecsni, Low et al. 2012). Nanodelivery 
systems may also enhance activity of bioactives in vivo through their controlled release 
properties (Kumari, Yadav et al. 2010), (Hu, Liu et al. 2011), (Hu, Lin et al. 2012).  
Nanoparticle behavior in vivo is affected by the properties of the particle, 
including size and surface charge (Mohamed and van der Walle 2008). Surfactants such 
as poly vinyl alcohol (PVA, Figure 1.1) are commonly used to enhance these properties 
(Mohamed and van der Walle 2008), (Sahoo, Panyam et al. 2002), (Astete, Kumar et al. 
2007). Concentration of surfactant will affect the properties of size, zeta potential, and 




Figure 1.1 Structure of poly (vinyl alcohol) 
 
 
Polymers selected for nanoparticle synthesis largely contribute to nanoparticle 
properties and their activity in vivo.  Poly (lactide co glycolide), PLGA, (Figure 1.2), for 
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example, is a FDA approved, biodegradable synthetic co-polymer of lactic acid and 
glycolic acid shown to improve stability and bioavailability of entrapped drugs (Anand, 
Nair et al. 2010),(Astete, Kumar et al. 2007). It is a highly biocompatible and 
biodegradable polyester (des Rieux, Fievez et al. 2006). PLGA is soluble in many 
different solvents, and is available in many different formulations so hydrophobicity of 
the NP can be optimized through ratio of lactic acid to glycolic acid of the PLGA selected 
for NP synthesis (Makadia and Siegel 2011).   
 
Figure 1.2: PLGA Structure  
 
Chitosan (chi), (Figure 1.3), a natural heteropolymer derived from chitin, is commonly 
used to supply a positive surface charge to a nanomaterial. Chitosan has been found to 
provide a stable means of encapsulation and to the positive zeta potential of the Chitosan 
NP was shown to improve cellular uptake of nanoparticles (Hu, Ting et al. 2012),(He, Hu 
et al. 2010).  
 
Figure 1.3: Low molecular weight chitosan structure  
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In the present study lutein was entrapped in PLGA and PLGA/Chitosan nanoparticles 
using PVA as a surfactant in an attempt to improve its efficacy as an antioxidant against 
peroxyl radicals. Chapter 2- Nanodelivery of Bioactive Components for Food 
Applications: Types of Delivery Systems, Properties, and their Effect on ADME Profiles 
and Toxicity of Nanoparticles and will further describe how different nanoparticle 
properties affect nanodelivery and functionality of the entrapped bioactive.  Chapter 3 
covers the synthesis and characterization of PLGA (lutein) and PLGA/Chitosan (lutein) 
NPs and compares the antioxidant functionality of nanoentrapped lutein to antioxidant 
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CHAPTER 2: NANODELIVERY OF BIOACTIVE COMPONENTS FOR FOOD 
APPLICATIONS: TYPES OF DELIVERY SYSTEMS, PROPERTIES, AND THEIR 




Antioxidants, probiotics, polyunsaturated fatty acids, and proteins are common bioactives 
that can be added to food to improve nutritional value. Food bioactives can be used to 
prevent diseases such as cancer and heart disease and to improve overall health(Jime ́nez-
Colmenero2013). Nanodelivery of these components in food may improve their stability 
(Trombino et al. 2009), solubility (Fathi et al. 2011), functionality (Swarnakar et al. 
2011), cellular uptake (Gaumet et al. 2010, Hamdy et al. 2009, Harush-Frenkel et al. 
2007, Hu et al. 2012, Li et al. 2010, Sahoo et al. 2002, Win & Feng 2005, Wang et al. 
2012, Yoo & Mitragotri 2010, Zhang et al. 2008), and bioavailability (Anand et al. 2010) 
and may also provide controlled release (Kumari et al. 2010) for better efficacy of the 
bioactive. 
“This chapter previously appeared as [T. Borel and C.M. Sabliov, Nanodelivery of 
bioactive components for food applications: types of delivery systems, properties, and 
their effect on ADME profiles and toxicity of nanoparticles in Annual Reviews of Food 
Science and Technology February 2014]. It is reprinted by permission of [Annual 
Reviews].” 
 
It is therefore widely accepted that nanoparticles may offer distinct advantages for 
delivery of bioactives, ranging from improving stability to controlling the release and  
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targeting of the bioactive for enhanced functionality. Due to the increasing interest in the 
use of nanoparticles for food and oral drug delivery, consumer safety has become a 
serious concern (Vega-Villa et al. 2008). Safety concerns stem from the potential of the 
nanoparticles to translocate to tissues due to their small size and the higher-than-
physiologically normal concentrations of the delivered bioactive in tissues. The type of 
nanoparticle and related chemical, physical, and morphological properties affect their 
interaction with living cells and also determine the route of clearance from the 
gastrointestinal (GI) system and possible toxic effects. 
 
Types Of Delivery Systems 
 
Nanodelivery systems (Figure 1) are classified into two main groups, liquid and solid. 
The three types of liquid nanodelivery systems are nanoemulsions, nanoliposomes, and 
nanopolymersomes. Nanoemulsions can be separated into either emulsions or stabilized 
emulsions. The three types of solid nanodelivery systems are lipid nanoparticles, 
polymeric nanoparticles, and nanocrystals. The group of lipid particles is composed of 
solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). Polymeric 
nanoparticles can take the form of nanospheres and nanoencapsulates. 
 
Emulsions and Stabilized Emulsions 
In its most simple form, an emulsion is the mixture of two immiscible liquids, generally 
oil and water. Nanoemulsion droplets measure between 10 and 100 nm in diameter and 
are typically transparent due to these sizes being on a scale smaller than the ultraviolet-
visible light range. Emulsions stabilized by surfactants or other types of stabilizing 
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agents, including phospho- lipids, amphiphilic proteins, or polysaccharides (Guzey & 
McClements 2006), namely stabilized. 
 
 
Figure 1: Classification of nanodelivery systems. Abbreviations: MLVs, multilamellar 
vesicles; SLVs, single lamellar vesicles 
 
emulsions, have been developed to provide controlled release, improved entrapment 
efficiency, and protection from degradation (Carrillo-Navas et al. 2012, McClements & 
Li 2010). In the instance of nanodelivery, the hydrophobic food bioactive is to be 
dissolved in the internal organic phase of an oil-in-water emulsion, whereas double 
emulsions are employed for delivery of hydrophilic molecules (Sapei et al. 2012). 
Two types of methods are commonly used in nanoemulsion synthesis, mechanical or 
chemical processes. Mechanical processes employing sonicators and microfluidizers are 
considered high- energy processes as mechanical forces are employed to break larger 
emulsion droplets into smaller ones. Low-energy or chemical methods result in 
spontaneous formation of emulsion droplets due to the hydrophobic effect of lipophilic 
molecules, in the presence of emulsifiers (McClements & Li 2010). Emulsions and 
stabilized emulsions are commonly used in the food industry. Emulsions of olive oil 
stabilized with sodium caseinate, whey protein concentrate, and polyglycerol ester were 
used to replace the animal fat in meat products (Cofrades et al. 2013); locust bean gum 
was used for reduced-fat salad dressings and desserts (Chung et al. 2013); additionally, 
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Liposomes are self-assembled nanoparticles formed from phospholipids in the form of a 
bilayer. Liposomes are ideal for carrying hydrophilic molecules due to the polar 
environment of the vesicle (Tamjidi et al. 2013). However, hydrophobic molecules can 
be delivered using liposomes as well, when these components are entrapped in the 
bilayer. When delivered with liposomes, the encapsulated materials are protected from 
external conditions. Another advantage is that liposomes can be made without the use of 
organic solvents (Madrigal-Carballo et al. 2010). Liposomes can be either unilamellar or 
multilamellar, referred to as small unilamellar vesicles (SUVs) and multilamellar large 
vesicles (MLVs), respectively. SUVs are in the range of 100 nm, whereas MLVs are 
commonly between 500 nm and 5 µm. 
Methods for synthesizing liposomes include the gentle hydration method (Wang et al. 
2010) and the layer-by-layer electrostatic deposition (Madrigal-Carballo et al. 2010). 
Liposomes have been developed for food applications as a method for creating iron-
enriched milk (Xia & Xu 2005), antioxidant delivery (Madrigal-Carballo et al. 2010), and 
codelivery of vitamins E and C with orange juice (Marsanasco et al. 2011). 
 
Polymersomes 
Polymersomes are vesicles formed from a bilayer of amphiphilic copolymers with 
bioactives en- trapped in the formed cavity (Bouwmeester et al. 2009), similar to 
liposomes. The difference is that a copolymer of amphiphilic nature is used instead of 
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phospholipids. Similarly to liposomes, Polymersomes can be used to entrap both 
hydrophilic and hydrophobic drugs. Advantages of polymer carriers, as opposed to lipid 
carriers, include controlled release and increased stabil- ity and versatility (Rastogi et al. 
2009). Polymersomes can be made with tri-block copolymers such as poly(caprolactone)-
poly(ethylene glycol)-poly(caprolactone) and can be synthesized using methods similar 
to those used for polymeric nanoparticles (Rastogi et al. 2009). 
 
Nanocrystals 
Nanocrystals consist of a bioactive surrounded by a surfactant (Florence 2005). 
Nanocrystals improve the solubility of poorly water-soluble drugs by increasing the 
surface-area-to-volume ratio, which increases the dissolution rate of the bioactive in vivo 
(Sun & Yeo 2012). The distinct advantage of nanocrystals is that they have 100% 
bioactive loading. Another advantage is that they can be prepared without organic 
solvents. Nanocrystals have shown not only improved solubility but also improved 
cellular interaction of the bioactive in nanocrystal form (Hunter et al. 2012). 
Nanocrystals can be made using mechanical or chemical methods (Sun & Yeo 2012). 
Starch nanocrystals are commonly prepared using acid hydrolysis, ultrasonication, and 
stirring to disperse and prevent the nanocrystals from aggregating (Kristo & Biliaderis 
2007, Xu et al. 2010). Wet milling is applied to reduce the size and increase the 
uniformity of the crystals (Sun & Yeo 2012). Another technique of forming nanocrystals 
is nanoprecipitation (Sun & Yeo 2012). Food grade starch and protein nanocrystals are 
being developed for various applications in the food and biomedical realms (de Mesquita 
et al. 2012, Flauzino Neto et al. 2013, Tzoumaki et al. 2011). 
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 Lutein nanocrystals for oral delivery are in the process of development, but lutein 
crystals in the 100-nm range have not yet been achieved (Mitri et al. 2011). 
 
Lipid Nanoparticles 
SLNs are similar to emulsions, with the exception that the lipids are in a solid phase. The 
lipids in these SLNs are digested at a slower rate than lipids in a liquid phase 
(McClements & Li 2010). An advantage of SLNs is that they provide a means of 
entrapping lipophilic molecules in stable particles without the use of organic solvents. 
SLNs have the potential to provide controlled release of various lipophilic components 
due to decreased mobility of the bioactive in the solid matrix (Mehnert & Ma ̈der 2012). 
However, these particles have a low loading efficiency and drug may be expelled during 
crystal structure transformation during storage (Tamjidi et al. 2013). NLCs are lipid 
nanoparticles with both crystallized and liquid phases of lipid used for nanodelivery 
(Tamjidi et al. 2013). The inner liquid phase dissolves and entraps the bioactive to 
provide the advantages of chemical stability, controlled release, and a higher loading 
efficiency (Tamjidi et al. 2013). 
High-energy methods are often used to synthesize SLNs and NLCs for food applications 
(McClements & Li 2010, Tamjidi et al. 2013), including microfluidization and 
ultrasonication (Mehnert & Ma ̈der 2012). Hot and cold homogenization techniques are 
able to form both SLNs and NLCs (Tamjidi et al. 2013). SLNs are often varied in size 
depending on the surfactant type and concentration; if the surfactant concentration is too 
low or too high, the SLNs will aggregate. The use of ionic surfactants often results in 
smaller particle sizes, and stability is increased by using more than one surfactant to 
stabilize the emulsion (Mehnert & Ma ̈der 2012). SLNs were developed for food 
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applications with the goal of improving guava shelf life (Zambrano-Zaragoza et al. 2013), 
the stability of quercetin (Li et al. 2009), beta carotene, and alpha tocopherol (Trombino 
et al. 2009). 
 
Polymeric Nanoparticles 
Polymeric nanoparticles are matrices of polymers and entrapped molecules surrounded 
by an emulsifier or surfactant (des Rieux et al. 2006, Hunter et al. 2012, Plapied et al. 
2011). Polymeric nanocapsules are nanoparticles in which the polymer forms a wall 
surrounding the entrapped core containing the bioactive; the polymer encapsulates the 
bioactive. These particles, nanospheres, and nanocapsules are designed to protect the 
entrapped bioactive from degradation (Mishra et al. 2010); polymeric particles can be 
engineered to have mucoadhesive or enhanced intestinal permeability (Chen et al. 2011). 
Methods of synthesizing polymeric nanoparticles include solvent displacement or 
nanoprecip- itation or desolvation, salting out, and emulsion evaporation methods 
(Sabliov & Astete 2008). Other methods are pH cycling, thermal treatment, atomization 
spraying, and the use of super- critical fluids; these are mostly applied to nanoparticle 
synthesis for proteins and hydrocolloids. Natural polymer nanoparticles such as gum 
arabic maltodextrin were developed to improve the stability and bioavailability of 
epigallocatechin gallate (Peres et al. 2011). Protein polymer (zein) nanoparticles 
successfully entrapped essential oils with antioxidant properties (Wu et al. 2012). Gelatin 
nanoparticles encapsulated polyphenol antioxidants to protect their antioxidant activity 
and provide controlled release (Shutava et al. 2009). 
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Properties of Nanodelivery Systems of Importance to Nano-Bio Interactions 
Physicochemical properties of the delivery systems will affect their absorption, 
distribution, metabolism, and excretion (ADME), which is essential in modulating the in 
vivo activity of the delivered bioactive. Properties of importance in nanoparticle in vivo 
interactions are size, charge, hydrophobicity, and targeting properties, among others 
(Figure 2). 
Size is important for entry into cells, immune cell stimulation, and particle clearance 
(Naahidi et al. 2013). Cell uptake mechanisms are partially dependent on size. 
Endocytosis is the process through which nanoparticles or small molecules enter cells; 
the specific type of endocytosis through which the nanoparticle enters the cell determines 
the translocation of the entrapped molecule inside the endosome (Sahay et al. 2010). The 
common sizes of vesicles formed through endocytosis are between 60 nm and 1,000 nm. 
Particles larger than 500 nm are not endocytosed by enterocytes; therefore, they are 
commonly excreted before reaching the bloodstream (Table 1) (Yoo & Mitragotri 2010). 
The size of particles may affect the immune response; the larger the particle, the more 
likely it is to be eliminated by cells in the mononuclear phagocyte system (MPS), which 
will reduce the nanoparticle blood circulation time (Choi et al. 2011). Nanoparticles be- 
tween 1 and 20 nm remain in the vasculature longer than larger particles; particles 
between 30 and 100 nm are able to evade the MPS and avoid clearance by macrophage 
cells, allowing for long circulation times (Table 1) (Faraji & Wipf 2009). 
Hydrophobicity affects cellular uptake, distribution, interaction with immune cells and 
plasma proteins, and clearance from the body (Naahidi et al. 2013). Hydrophobic 
nanoparticles diffuse 




Figure 2: Chemical, physical and morphological properties and their effect on in vivo 
interactions. Reprinted with permission from Macmillan Publishers, Ltd. (Nature), 
copyright 2013 (Naahidi 2013).  
 
 
into epithelial cells more easily than hydrophilic particles because of a large activity 
coefficient (Table 1) (Acosta 2009, Powell et al. 2010). Hydrophobic nanoparticles are 
recognized as foreign substances by macrophages of the MPS present in the blood and 
are often cleared through biliary excretion (Table 1) (Bertrand & Leroux 2012, Naahidi et 
al. 2013). 
Hydrophilic nanoparticles may be quickly cleared from the kidney if they are smaller 
than 10 nm (Table 1) (Choi et al. 2011). Hydrophilic nanoparticles are less likely to be 
recognized as foreign objects in the blood (Naahidi et al. 2013). Hydrophilic 
nanoparticles traverse through mucus at a rate faster than that of hydrophobic particles 
due to hydrophobic interactions in the mucus layer (Lai et al. 2009). 
 17 
Table 1: Ranking of characteristics for absorption, distribution, and excretion 
 
	   18	   	  
Table 1 (Continued) 
 
 
Charge is important for entry into cells, immune cell stimulation, plasma proteins, and 
toxic- ity (Naahidi et al. 2013). Positive charges are more prone to promote an immune 
response than negative and neutral charges (Table 1) (Bertrand & Leroux 2012, Naahidi 
et al. 2013). Nanopar- ticles without charge are able to remain in the bloodstream for a 
longer time than positively or negatively charged particles, and negative charges are 
associated with longer circulation times in mice than positive charges (Bertrand & 
Leroux 2012). 
Targeting affects nanoparticle distribution and immune response (Naahidi et al. 2013). 
Targeting molecules may exploit receptors to gain entry into specific types of cells 
(Markovsky et al. 2012).  
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The physical and chemical properties, specifically size and surface charge, of the 
targeting molecule affect its immune response (Markovsky et al. 2012). 
 
Adsorption, Distribution, Metabolism, And Excretion (ADME) of Nanoparticles 
 
The ADME profile of a nanoparticle is greatly determined by properties such as size, 
charge, hydrophobicity, and targeting molecules, and these properties are dependent on 
the type of delivery system (Card et al. 2011). Nanoparticle ADME (Figure 3) will 
determine the potential toxicity. 
 
Figure 3: Flow chart describing a nanoparticle’s path through the body from ingestion to 
excretion 
 
of the nanoparticle (Bouwmeester et al. 2009). Absorption refers to the nanoparticle 
interaction with the gut mucosa and epithelial cells, which ends in the nanoparticle 
entering into systemic circulation. Distribution or biodistribution occurs through systemic 
circulation, during which the particles are distributed to organs such as the liver, kidneys, 
spleen, heart, lungs, and brain. Metabolism describes the biotransformation of the 
nanoparticle that occurs through interactions with proteins and lipids in tissues such as 
the liver and intestinal tissue.  
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The liver, kidneys, and colon are primarily responsible for excretion of nanoparticles and 
their metabolites (Bertrand & Leroux 2012, Bouwmeester et al. 2009). 
 
Ingestion 
Knowledge of the fate of nanoparticles in the GI tract is needed to optimize delivery 
systems for improvement of bioavailability of food nutraceuticals. Ingested nanoparticles 
begin their GI journey when they enter the mouth and are partially digested through 
saliva and mastication at a pH between 5 and 7 (McClements & Li 2010). Then the 
nanoparticles enter the stomach through the esophagus, where they will remain for 30 
min to 4 h, depending on whether the stomach is in a fasting or fed state (Kompella & 
Lee 2001, McClements & Li 2010). The acidic pH of the stomach (between 1 and 2), 
along with enzymes, is designed to break down proteins and carbohydrates (Ensign et al. 
2012). If the nanoparticle is made out of hydrocolloids and proteins, degradation of the 
nanoparticles can be significant under the extreme pH of the stomach. Assuming that the 
particles are able to withstand the acidic pH and remain suspended in the media as an 
integral nanoparticle, they travel to the small intestine. Nanoparticles enter the intestines 
through the duodenum, where they are introduced to a pH between 6 and 7.5 and various 
bile salts from the gall bladder that are designed to emulsify fats (Kompella & Lee 2001, 
McClements & Li 2010). Nanoparticles remain in the small intestines for 3–6 h before 
traveling to the large intestine or colon (Kompella & Lee 2001, McClements & Li 2010). 
It is mainly in the small intestine that the nanoparticle and/or the released bioactive are 
absorbed. 
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Absorption 
For nanoparticles to be absorbed, they have to overcome enzymes, the low pH of the 
stomach, the mucosal lining of intestines, and the cellular membranes with selective 
permeability (Chen et al. 2011, Ensign et al. 2012). The inner surface of the small 
intestine contains epithelial cells for the uptake of necessary nutrients or nanoparticles. 
These cells are covered in microvilli and mucus to help them absorb various nutrients and 
avoid absorption of harmful chemicals. Enterocytes in the small intestine are covered 
with a thin layer of firmly adherent mucus and a thick layer 
 
Figure 4: Mechanisms of entry into cells (Sahay et al. 2010). Abbreviations: CCVs, 
clathrin-coated vesicles; CLICs, clathrin-independent carriers; GEEC, 
glycosylphosphatidylinositol-anchored protein-enriched compartment. Reprinted from J. 
Control. Release, Vol 145(3), Guarav Sahay, Daria Y. Alakhova, Alexander V. Kabanov, 
Endocytosis of Nanomedicines, Page 14, Copyright (2010), with permission from 
Elsevier.  
 
of loosely adherent mucus making it the easier for nutrients to be absorbed (Ensign et al. 
2012). The surface properties and concentration of the particles determines the type of 
transport and extent of nanoparticle absorption. The optimal size for mucous transfer is 
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less than 100 nm, which is the average pore size of human mucus (Lai et al. 2007, 2009). 
However, a nanoparticle size of 200 nm is preferred over one of 100 nm because 200-nm 
nanoparticles have three times the diffusion coefficient of 100-nm nanoparticles (Acosta 
2009) (Figure 3). The size cutoff for mucosal transfer is approximately 500 nm (Norris et 
al. 1998). M cells in Peyer’s patches make up approximately 1% of intestinal cells, and 
they are able to absorb large particles of approximately 1 µm as well as small particles of 
approximately 100 nm. Particles may enter M cells through endocytosis such as clathrin-
mediated endocytosis or fluid-phase endocytosis (Florence 2005). Enterocytes are 
responsible for the rest of the cellular uptake in the intestine through clathrin- mediated 
endocytosis, caveolea-mediated endocytosis, macropinocytosis, caveolea, and clathrin- 
independent endocytosis (Figure 4) (Sahay et al. 2010). Nanoparticles endocytosed via 
clathrin- mediated endocytosis enter early endosomes with a low pH and eventually enter 
lysosomes in which they will be metabolized. Nanoparticles that enter cells via caveolea-
mediated endocytosis are enveloped in caveosomes, which enter the nucleus. 
Nanoparticle transport through cellular membranes and organelles is dependent on cell 
type, surface charge, nanoparticle composition, and hydrophobicity. Nanoparticle path 
and localization within the cellular environment will be responsible for functionality of 
the entrapped bioactive. 
 
Distribution and Metabolism 
Following absorption through the gut, very hydrophobic nanoparticles are transported to 
the lymph, if they are taken up in the gut-associated lymphoid tissue and reach lymphoid 
circulation (Bouwmeester et al. 2009); alternatively, particles can be sent to the liver via 
the hepatic portal vein, if they are not taken up by the gut-associated lymphoid tissue. 
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The liver is where they are processed and sent to systemic circulation (Chen et al. 2011) 
(Figure 3). 
If the nanoparticles enter the lymph, they will reach circulation before being metabolized 
in the liver (Hunter et al. 2012). This is one way that nanoparticles are able to bypass 
first-pass metabolism and increase concentration of bioactives in the bloodstream. The 
lymphatic system delivers the nanoparticles to systemic circulation through the caudal 
vena cava (Lu et al. 2010). Upon reaching systemic circulation, nanoparticles are 
transported to various organs such as the heart, lungs, spleen, kidney, liver, and 
potentially the brain (Aillon et al. 2009). Organs with higher blood flow such as those 
listed above are exposed to higher concentrations of nanoparticles (Faraji & Wipf 2009). 
The metabolism of nanoparticles greatly depends on the type of nanoparticle. Polymeric 
and lipid nanoparticles are often designed to be biodegradable. Natural polymers such as 
proteins and carbohydrates are degraded in the digestive tract via enzymes. Little 
information is known on the metabolic processes of nanoparticles and their components. 
 
Excretion 
Nanoparticles can also pass by the epithelial cells and mucus without being absorbed; if 
this happens, nanoparticles enter the colon directly, and they are prepared for excretion. 
From the liver, the nanoparticles may also reenter the intestines for excretion (Lu et al. 
2010). Hydrophilic particles may be excreted through the kidneys into the urinary tract if 
they are smaller than 10 nm (Choi et al. 2011) (Figure 3). 
Nanoparticles can be designed to improve absorption, enhance distribution, and reduce 
excretion (Table 2). Neutrally charged, hydrophobic nanoparticles that are smaller than 
100 nm are 
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Table 2: Optimal characteristics of nanodelivery systems for improved absorption, 
distribution, and excretion 
 
ideal for absorption. Neutrally charged, hydrophilic nanoparticles that are smaller than 
100 nm remain in circulation longer, making them ideal for distribution. Hydrophilic 
nanoparticles smaller than 5 nm are excreted via the kidneys. Nanoparticles larger than 
500 nm are not likely absorbed in the intestines and are excreted in the feces. 
 
Fate of Bioactives 
 
The entrapped bioactive is eventually released into the body either in the intestines, 
during systemic circulation, or in the cells of organ tissues (Bouwmeester et al. 2009, 
Chen et al. 2011). The surface chemistry of the nanodelivery system is responsible for the 
time and location of the release. Release can be stabilized through the use of polymers 
such as alginate or chitosan, which are applied in a layer-by-layer technique to prevent a 
burst release (Quintanilla-Carvajal et al. 2009).  
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The location of release can be controlled through the use of polymers that are sensitive to 
a specific pH range. For example, PEG has been shown to increase pH-stimulated 
lysozyme release (Quintanilla-Carvajal et al. 2009). 
If released into the intestines, the bioactive will undertake intracellular trafficking into 
enterocytes or M cells. The chemical, morphological, and physical properties of the 
bioactive will deter- mine the rate, method, and gravity of uptake (Sahay et al. 2010). 
Non-ionic hydrophobic bioactives will be taken up in greater quantities than charged or 
hydrophilic molecules (Florence 2005). The bioactive may remain in the intestinal cells; 
it may be released into the lymphatic system, or it may be released into a portal vein 
routing it to the liver (Hunter et al. 2012, Markovsky et al. 2012). 
If released into systemic circulation, the properties of the bioactive will determine how it 
interacts with blood components. A hydrophilic non-ionic bioactive will remain in 
circulation longer than a hydrophobic bioactive due to the hydrophobic and electrostatic 
interactions required for plasma proteins to bind to molecules (Sheng et al. 2009). 
If released into the cells of organ tissues, cellular interactions will determine the 
intracellular trafficking of the bioactive (Sahay et al. 2010). The method of entry the 
nanoparticle employed to enter the cell will determine the location of bioactive release. If 
lysosomal release occurs, small hydrophobic molecules are able to escape the endosome 
or lysosome membranes, and large or hydrophilic molecules will remain inside the 
lysosomes (Romberg et al. 2008). Bioactives may follow the pathways of typical water-
soluble or fat-soluble biomacromolecules depending on their chemical and physical 
properties (Sahay et al. 2010). 
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Safety Of Nanoparticles For Bioactive Delivery 
Nanotechnology application in the food and agriculture sectors has been hindered to 
some extent by concerns about the safety of the engineered nanoparticle (ENP), as well 
as ethical, policy, and regulatory issues (Food Agric. Org. & World Health Org. 2012), 
all rooted in the lack of knowledge about the potential effects of nanomaterials on human 
health and the environment. Large differences in the toxicokinetic properties for ENPs of 
varying types are expected (European Com- mission 2009). Even for the same type of 
ENP, when nanoparticles do not show any acute toxicity, questions of long-term effects 
and bioaccumulation remain unanswered (Tiede et al. 2008). For poly(lactic-co-glycolic) 
acid (PLGA) ENPs, making up a well-studied biodegradable and biocompatible 
polymeric delivery system, little to no histopathological changes were found in tissues 
derived from animals treated orally with PLGA nanoparticles. For example, high doses of 
PLGA ENPs (4 mg/0.2 ml) did not lead to any tissue lesions as compared to the same 
high dose of ZnO nanoparticles that led to toxicity in Balb/C mice (Semete et al. 2010). 
Similarly, in Sprague Dawley rats, histopathological examination of tissue indicated 
absence of any inflammatory response in the liver and spleen (Mittal et al. 2007). 
Cationic bovine serum albumin–PLGA ENPs showed mild 
and transient inflammatory reactions in the liver and kidney; mild reactions in the spleen; 
and no reaction in the cerebral cortex, hippocampus region, cerebellum, lung, or heart 
(Lu et al. 2007).To date, little work has been done in vivo to evaluate the fate of 
polymeric nanoparticles purposely designed for food and agricultural uses (European 
Commission 2009) and to correlate with the fate of nanoparticles after ingestion with 
their possible toxic effects. The challenge for characterizing nanoparticles with regard to 
human toxicity is due to the diversity of the size, shape, and surface chemistry  
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(Elder et al. 2009) of ENPs. In addition, agglomeration, degradation, and mucus 
interaction of particles as a function of ENP material composition and surface 
characteristics will dictate the ADME profile of the ENPs and inherently ENP safety. 
Nanoparticles made of food grade materials, intended specifically for food and 
agriculture uses, are expected to be nontoxic to the animal host on the premise that the 
materials used in the ENP synthesis are carefully selected to hold generally-recognized-
as-safe status. Yet, ENP safety to humans and farm animals exposed to nanoparticles is a 
major concern, and understanding the effect of the particle type and properties on the fate 
of the nanoparticle in the GI tract, of ENP uptake, and of biodistribution as well as the 
potential toxic effects is critically important for the responsible development and use of 
ENPs in food and agriculture. 
Toxicological studies provide information on carcinogenicity, teratogenicity, 
reproductive toxicity, developmental toxicity, and neurotoxicity of the nanoparticle prior 
to their use (Cockburn et al. 2012). Cockburn et al. proposes a two-tiered system for 
engineered nanomaterial (ENM) safety characterization, where in silico, in vitro, and 
subacute in vivo studies comprise tier 1 and acute in vivo studies make up tier 2. In tier 1, 
the beginning criteria to evaluate engineered nanodelivery systems are biodegradability, 
biocompatibility, and solubility compared to their microscale counterparts.  
 
The metabolism and elimination profiles of the nanomaterial are important factors to 
consider in preventing accumulation of the nanodelivery systems in tissues and clearance 
organs (Markovsky et al. 2012). In silico studies provide computed data describing the 
potential toxicity and ADME profile. In vitro studies use real or simulated biological 
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material to determine possible cytotoxicity, genotoxicity, reactive oxygen species 
generation, inflammatory response, and chemical degradation of nanomaterials. In vivo 
studies offer data on toxicity, genotoxicity, and the ADME profile; for tier 1, the 
suggested timeline for in vivo repeat dosing is 14 or 28 days (Cockburn et al. 2012). In 
tier 2, the dosing time for in vivo studies increases to an acute dose time of 90 days to 
determine carcinogenicity, reproductive toxicity, neurotoxicity, and teratogenicity 
(Cockburn et al. 2012). 
Safe application of nanoparticles to food and agriculture requires the nanoparticle 
characterization, functionality, ADME profile, and toxicity to be determined. A tiered 
approach to ENM testing provides a means to establish the type and quantity of 




Nanodelivery systems offer a multitude of physical and chemical advantages for 
improved bioavailability and stability of bioactives. Each type of nanodelivery system 
offers distinct benefits, and the properties of the bioactive along with the purpose of 
delivery should determine which nanoparticle type is most appropriate for the 
application. The system’s chemical, physical, and morphological properties will 
determine the nano-bio interaction and ADME profile. Properties of importance for 
cellular and immunological interaction are size, charge, hydrophobicity, and targeting 
molecules. Degradation in the stomach (low pH, presence of enzymes), the presence of 
the firmly adherent mucosal lining, selectively permeable epithelial and M-cell 
membranes, as well as enzymatic degradation in the intestines hinder uptake of the 
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nanodelivery system and bioactive absorption. Upon absorption, the nanodelivery system 
must evade the MPS, which will remove nanoparticles from systemic circulation. 
Distribution of the nanodelivery system begins once nanoparticles enter systemic 
circulation through the lymph or caudal vena cava. The fate of the bioactive greatly 
depends on where it is released, but it also depends on its chemical, physical, and 
morphological properties. The location of bioactive release can be tailored using nanoma- 
terials with specific surface chemistry, enabling release at the target. A layer-by-layer 
approach for engineering the nanodelivery system prevents the burst release of the 
bioactive and ensures a gradual release profile of the bioactive. The safety of 
nanodelivery systems is determined by the materials’ biocompatibility, biodegradability, 
and nanoparticle ADME profile. A combination of in silico, in vitro, and in vivo studies 
reveals the safety and toxicological profile of the nanodelivery system and is required for 




1. Nanodelivery of food bioactives enhances their bioavailability and biodistribution 
through the improvement of their uptake, stability, and solubility. 
2. Nanodelivery systems are classified into two main groups, liquid and solid. Liquid 
particles can be nanoemulsions, nanoliposomes, or nanopolymersomes. Solid particles 
consist of nanocrystals, lipid particles, or polymeric particles. 
3. Physicochemical properties of importance for nano-bio interaction include nanoparticle 
size, charge, hydrophobicity, and targeting molecules, among others. Size is important for 
nanoparticle entry into cells, immune system interactions, and nanoparticle clearance. 
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Hydrophobicity affects absorption, distribution, interaction with immune cells and 
plasma proteins, and route of excretion. Charge is important for mucoadhesion 
or diffusion, cellular uptake, and toxicity. Targeting affects biodistribution and immune 
responses. 
4. Orally delivered nanoparticles must overcome the chemical and physical barriers to ab- 
sorption, which include the acidic pH of the stomach and enzymes, the loosely and firmly 
adherent mucosal linings of the intestines, and selectively permeable enterocyte 
membranes. 
5. The entrapped bioactive is eventually released in the intestines, in the circulatory 
system, or in the cells of various organs. The location of release and the chemical and 
physical properties of the bioactive determine its biological fate. 
6. The safe application of nanoparticles in food and agriculture require knowledge of 
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Unsaturated fatty acids and lipids are a prime target of oxidation in foods and biological 
systems (Laguerre, Lecomte et al. 2007). Macular degeneration and cataracts, UV 
induced sun damage, and risk of atherosclerosis can be decreased by enhanced 
consumption of foods or supplements containing lutein (Kritchevsky, Bush et al. 2000; 
Dwyer, Navab et al. 2001; Krinsky, Landrum et al. 2003; Alves-Rodrigues and Shao 
2004; Lee, Faulhaber et al. 2004).   
Lutein, a dietary antioxidant (Figure 3.1), is essential for diminishing photo-induced 
oxidative stress and is useful for filtering high energy blue light in the lens and macula 




Figure 3.1 Lutein Structure 
Lutein is reactive at quenching both singlet oxygen radicals, formed through UV 
photonic exposure (Laguerre, Lecomte et al. 2007), and peroxyl radicals, which result 
from the oxidation of unsaturated fatty acids (Kiokias and Oreopoulou 2006). Singlet 
oxygen radicals are electrophilic and form hydroperoxides, which break down into 
radicals causing autoxidation of lipids. Hydroxyl, hydroperoxyl, peroxyl, and lipid 
HO
OH
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alkoxyl radicals are mainly responsible for non-enzymatic lipid oxidation, which results 
in the formation of toxic hydroxy and ketocholesterols (Laguerre, Lecomte et al. 2007; 
Lordan, Mackrill et al. 2009). In the macula lutea of the eye, cholesterol is photooxidized 
to 7-ketocholesterol and 7α and β-hydroxycholesterols, process linked to macular 
degeneration (Breuer, Dzeletovic et al. 1996; Rodriguez and Larrayoz 2010).  
Lutein is easily oxidized by photooxidation or free radicals; therefore providing a 
means of improving its chemical stability until use would preserve the efficacy of the 
antioxidant (Lakshminarayana, Aruna et al. 2008). Release of preserved antioxidant over 
time, providing radical scavenging benefits for extended periods of time, would further 
aid in enhancing its activity for long-term applications.  
Nanodelivery systems have been proposed as alternatives for improving stability, 
release and functionality of bioactives. It has been shown for example that chemical 
stability of quercetin, alpha-tocopherol, and beta-carotene was protected using chitosan 
and solid lipid nanoparticles (Trombino, Cassano et al. 2009; Luo, Zhang et al. 2010), 
while PLA, PLGA, and zein nanoparticles were previously developed to provide 
controlled release of other hydrophobic drugs and antioxidants (Kumari, Yadav et al. 
2010; Hu, Liu et al. 2011; Hu, Lin et al. 2012). Of the studies focused on entrapping 
antioxidants in nanoparticles many are centered on nanoparticle characteristics, 
antioxidant stability and release, and very few on the effect of the delivery system on the 
efficacy of the antioxidant (Bala, Bhardwaj et al. 2006; Pool, Quintanar et al. 2012).  
 
The goal of this study was to determine if stability and antioxidant activity of 
lutein could be improved by entrapping the bioactive into polymeric nanoparticle of 
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different surface properties. The hypothesis of this study was that by providing controlled 
release and protection from degradation of entrapped lutein into polymeric nanoparticles 
made of poly(lactic-co-glycolic) acid ( PLGA) will improve its antioxidant activity. 
Furthermore, it was hypothesized that the addition of chitosan on the nanoparticle surface 
will enhance the antioxidant efficacy by acting as a co-antioxidant; chitosan like lutein is 
a singlet oxygen scavenger (Xie 2001; Xing, Liu et al. 2005; Yen, Yang et al. 2008). 
Two nanoparticle types of a similar size, PLGA (lutein) and PLGA/Chitosan 
(lutein), were used in this study. The particles differed in surface charge due to the 
positively charged chitosan on the surface of PLGA/Chitosan (lutein) NPs. Release and 
degradation of lutein were assessed in Tween 20 emulsions in the presence and absence 
of the chemical initiator, 2,2′-azobisamidinopropane dihydrochloride (AAPH) using 
spectrophotometry. Antioxidant activity was evaluated using a cholesterol assay to 
determine the effect of NP entrapment on the antioxidant efficacy of lutein.  
 
Materials and Methods 
 
Materials: PLGA (50:50; Mol. Wt. 30,000-60,000) was purchased from Sigma Aldrich 
(St. Louis, Missouri). Koumin Foods, LLC (Des Moines, IA) provided lutein. Poly (vinyl 
alcohol) (PVA; Mol. Wt. 9000), ethyl acetate, acetonitrile, (2,2′-azobisamidinopropane 
dihydrochloride) AAPH, Tween 20, and all other chemicals were purchased from Sigma 
Aldrich (St. Louis, Missouri). 
 
Synthesis: Poly (D, L-Lactide-co-glycolide) nanoparticles (NPs) with entrapped lutein 
and blank polystyrene NPs (as a control) were prepared using emulsion evaporation. The 
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organic phase was made up of 200 mg of PLGA and 20 mg of lutein (10% loading), 
which were dissolved in 8mL of ethyl acetate. The organic phase was added via a syringe 
to 40mL of an aqueous phase containing 2% w/v PVA in deionized water and 4 mL of 
ethyl acetate at 300 rpm. The emulsion was run three times through the microfluidizer at 
30000psi for uniform size reduction. Solvent evaporation occurred under vacuum (70 mm 
Hg) for 60 minutes by rotovap (Buchi R-124, Buchi Analytical Inc., New Castle, DE, 
USA). Residual lutein and PVA were removed through dialysis membranes with 
MWCO: 100,000 Daltons. PLGA/Chitosan NPs were made by adding low molecular 
weight chitosan to PLGA NPs after dialysis under stirring at a pH of 3 in a ratio of 1:10, 
Chitosan to PLGA. Polystyrene NPs were made exactly as PLGA NPs without the 
addition of lutein. After dialysis, trehalose was added in a (1:1) w/v ratio, and particles 
were lyophilized using Freezone 4.5 (Labconoco Corp., Kansas City, MO, USA) for 72 
hours. Freeze dried particles were stored at 0°C until analysis.  
Size Analysis and Morphology: Hydrodynamic radius, size distribution, and 
polydispersity index was determined by dynamic light scattering with a Zetasizer 
(Malvern Instruments, Malvern, UK). Transmission electron microscopy (TEM) was 
used for morphology studies of the particles. Zeta potential was also measured with the 
Zetasizer using the Helmholtz-Smoluchowski equation.  
Entrapment: Extraction was performed to remove entrapped lutein from nanoparticle 
powder. An amount of 6 mg of powder was suspended in 600 µL of water using 
sonication and next 5.4 mL of acetonitrile was added. The mixture was allowed to set for 
4 hours, and the 6 mL sample was centrifuged at 30,000 rpm for 15 minutes at 8 ° C. The 
absorbance of the supernatant was measured on a UV-Vis spectrophotometer (Genesys 6, 
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Thermo Fisher Scientific, Waltham, MA) at 450 nm for detection of lutein. The 
absorbance value was used to calculate the concentration of lutein entrapped using a 
standard curve. The limit of detection on the spectrophotometer for lutein was calculated 
to be 3.8 µg/mL. 
Cholesterol Oxidation: An emulsion was made with 1000 mg of cholesterol with 10 mL 
of tween 20 in one liter of nanopure water. AAPH was used as an initiator at a 
concentration of 100 ppm. Each lutein sample was mixed with 27 mL of the cholesterol 
solution and 3 mL of AAPH for a final lutein concentration of 94 µM. The solution was 
continuously stirred for 72 hours at 37 °C as a model for human body temperature. 
Samples were taken for HPLC analysis at 0, 24, 48, and 72 hours to determine the level 
of 7-ketocholesterol, the oxidation product of cholesterol. The HPLC analysis method 
used for 7-ketocholesterol determination was obtained from Xu et al. (Xu, Hua et al. 
2001). A 1 mL sample was taken and mixed with hexane. Centrifugation at 5,000g for 10 
minutes was performed to remove the aqueous portion of the sample.  Sodium sulfate 
was used to further remove any moisture before injecting the sample. The sample was 
analyzed using a Waters 2690 separation module with a silica normal phase column and a 
mobile phase of hexane: isopropanol (99%: 1%) was used at a 1.5 mL/min flow rate. 
Detection of 7-ketocholesterol (UV wavelength of 234 nm) was done using a 996-
photodiode array detector and a Millennium chromatography station (Milford, MA). The 
concentration was calculated using a standard curve of 7-ketocholesterol (Tian, Wang et 
al. 2011).  
Physical Stability of lutein-loaded nanoparticles in emulsion environments: The physical 
stability of NP, with entrapped lutein in the cholesterol emulsions was assessed using the 
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Zetasizer (Malvern Instruments, Malvern, UK). Change in size, PDI, and zeta potential of 
the NPs were monitored for 72 hours in the cholesterol emulsion using the methods 
described above. Chemical stability of lutein emulsified and entrapped in PLGA (lutein), 
and PLGA/Chitosan (lutein) nanoparticles was measured for up to 24 hours in emulsions 
with and without AAPH.   
Localization in the emulsion environment: Confocal imaging was used to determine the 
localization of NP lutein in the linolenic acid emulsion. Linolenic acid emulsion droplets 
were stained using oil red (excitation: 589 nm, emission: 615 nm). Fluorescently labeled 
PLGA with fluorescein isothiocyanate, FITC, (excitation: 495 nm, emission: 519 nm) 
were used in this study. All images were taken using a Leica TCS SP2 Spectral Confocal 
Microscope (Buffalo Grove, IL).  
Statistical Analysis: All experiments were performed in triplicate, and all data was 
analyzed for statistical difference (Adj P < 0.05) using the PROC MIXED with the 




Size, Morphology, Zeta Potential and Remaining PVA analysis:  
PLGA (lutein) NPs measured 119 nm ± 0.98 nm in size, and PLGA/Chitosan (lutein) NPs 
were 146 ± 3 nm in diameter when measured in nanopure water (Table 3.1) with PDIs of 
0.17± 0.02 and 0.25 ± 0.01, respectively. Zeta potentials in nanopure water of PLGA 
(lutein) NPs and PLGA/Chitosan (lutein) NPs were -29 ± 1 and 21 ± 2 mV, respectively 
(pH 6.8). The remaining PVA surfactant after dialysis was corresponding 11 ± 1 and 10 ± 
1% of PLGA (lutein) and PLGA/Chitosan (lutein) NP structure, respectively. Based on 
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TEM pictures, PLGA(lutein) NPs appeared to be spherical and uniform in size, while 
PLGA/Chitosan (lutein) NPs appeared to be nearly spherical with a rough outer coating 
(Figure 3.2).  Entrapment efficiency measurements revealed that 21.8 ± 0.63 µg and 20.2 
± 0.62 µg lutein per mg of nanoparticles was entrapped in the PLGA (lutein) and 
PLGA/Chitosan (lutein) nanoparticles, respectively. 
 
Table 3.1 Nanoparticle physical/chemical properties, including size, polydispersity, zeta 
potential and surfactant concentration for PLGA and PLGA/Chitosan nanoparticles with 
entrapped lutein   
 
Nanoparticle 
Type Size (nm) PDI (units) 
Zeta Potential 
(mV) 
PVA Surfactant  
(mg PVA/mg Particle) 
PLGA (Lutein) 
119.2 ± 
0.98  0.17 ± 0.02 -29  ± 1.10 0.05  ± 0.00 
PLGA/Chitosan 




Figure 3.2: TEM images of A) PLGA (lutein) and B) PLGA/Chitosan (lutein) NPs 
A) PLGA (lutein)                                       B) PLGA/Chitosan 
(lutein) 
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Physical stability of NPs at 37 °C in the presence of Tween 20 emulsions was evaluated 
using DLS, as these conditions were employed for cholesterol oxidation experiments. 
PLGA and PLGA/Chitosan NPs with entrapped lutein remained stable for 24 hours in the 
tween emulsion (Figure 3.3). Sizes increased at 48 hours and retained the larger size until 
72 hours, but size changes over time were not found statistically different (Figure 3.3).  
 
 
Figure 3.3: Size Stability of NPs in Tween Emulsions at 37°C 
 
Lutein chemical stability was determined by measuring the amount of lutein present in 
the NP over time at 37 °C in the presence and absence of a radical initiator, AAPH. 
Chemical stability of NP entrapped lutein was compared to a Tween 20 lutein emulsion. 
In the presence of AAPH, 71% ± 15% of the lutein remained after 12 hours, and 50% ± 
30% remained after 24 hours in the emulsified form, whereas in the PLGA (Lutein) NP 
emulsion, 81%  ± 3% of the lutein was still available after 12 hours, and 65%± 10% after 
24 hours. In the PLGA/Chitosan (lutein) NP emulsion 84%  ± 7% lutein was preserved 
after 12 hours, and 60%  ± 28% after 24 hours (Figure 3.4 A). These changes over time 
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were not statistically significant.  In the absence of AAPH, 0% of lutein in emulsified 
lutein, PLGA (lutein) NPs and PLGA/Chitosan (lutein) NPs was degraded over 24 hours 
(Figure 3.4 B).  
  
  
Figure 3.4: Chemical Stability of lutein in Tween Emulsions in the A) presence and B) 
absence of AAPH at 37 °C: Results are reported as the percentage of lutein remaining in 
the NP or in the emulsion at 12 and 24 hours.  
 
Release of lutein from the nanoparticles suspended in the cholesterol emulsions 
was examined and PLGA NPs showed 50% release of lutein after 24 hours and 89% 
release after 72 hours. PLGA/Chitosan NPs showed 23 % release of lutein after 24 hours 
and 69% release after 72 hours from PLGA NPs. The change in percent of lutein release 
was statistically significant for each time point and was statistically different between 
A)	  
B)	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PLGA (lutein) and PLGA/Chitosan (lutein) NPs (Figure 3.5) with more lutein being 
released from PLGA (lutein) than from PLGA/Chitosan (lutein) NPs.  
 
    
Figure 3.5: Release of Lutein in Cholesterol Emulsion: PLGA NPs and PLGA/Chitosan 
NPs over 72 hours  
 
Cholesterol Oxidation 
Cholesterol oxidation results in the formation of 7-ketocholesterol; this compound can be 
extracted and measured using normal-phase high-pressure liquid chromatography. 
Presence of 7-ketocholesterol is associated with a low effectiveness of entrapped lutein as 
an antioxidant and can be used to determine lutein antioxidant activity over time. 7-
ketocholesterol concentrations are shown for blank control and lutein treatments at 24, 
48, and 72 hours (Figure 3.6).  
No statistical difference was found between the unloaded treatments and the control at 24 
hours (Figure 3.6 A). Polystyrene NPs showed no difference in the amount of 7-
ketocholesterol present after 24, 48, and 72 hours when compared to the blank control, 
0%	  10%	  20%	  
30%	  40%	  50%	  
60%	  70%	  80%	  
90%	  100%	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whereas blank PLGA significantly reduced the oxidation of cholesterol at 72 hours and 
PLGA/Chi unloaded nanoparticles significantly inhibited cholesterol oxidation at 48 and 
72 hours (Figure 3.6 A). At 24 hours no statistical significance was found between lutein 
loaded treatments, free lutein, and control (Figure 3.6 B). Lutein, PLGA (lutein), and 
PLGA/Chitosan (lutein) showed significantly lower concentrations of 7-ketocholesterol 
at 48 hours versus the control. PLGA/Chitosan (lutein) was significantly lower than 
lutein at 48 and 72 hours when compared to the control (Figure 3.6 B).   
 
 
Figure 3.6 A): 7-Ketocholesterol Concentrations at 37 °C for Blank NP Treatments: 24, 
48, and 72 hours * Empty PLGA and PLGA/Chitosan significantly lower than Control B) 
7-Ketocholesterol Concentrations at 37 °C for Lutein NP Treatments: 24-Hours, 48 
hours, and 72 hours *A Lutein, PLGA(lutein), PLGA/Chitosan (lutein) significantly 














PLGA and PLGA/Chitosan nanoparticles with entrapped lutein were synthesized by 
emulsion evaporation method, using poly (vinyl alcohol) as a surfactant. All particles 
were determined to have a similar size, but differed in zeta potential due to the addition 
of positively charged chitosan. Stability, release and antioxidant activity of lutein were 
assessed in Tween 20 emulsions. Lutein stability in the presence and absence of the 
chemical initiator, 2,2′-azobisamidinopropane dihydrochloride (AAPH) and lutein release 
were assessed using spectrophotometry. Antioxidant activity of free and entrapped lutein 
was evaluated by cholesterol oxidation analysis to assess the effect of entrapment and 
nanoparticle properties on the activity of the bioactive. 
 
PLGA (119.2 nm) and PLGA/Chitosan (145.9 nm) nanoparticles loaded with 21.8 ± 0.63 
and 20.2 ± 0.62 µgs lutein/ mg NP, respectively were used in these studies. In terms of 
size stability over time, PLGA nanoparticle size increased by 30 nm over the 72 hour 
period, and the PLGA/chitosan nanoparticle size increased by 50 nm over the 72 hour 
period at 37 °C, but the difference was not found statistically significant.  Overall, 
nanoparticles maintained their size stability over time under conditions relevant for 
antioxidant experiments. Chemical stability of lutein was tested in the presence and 
absence of the oxidizing agent, AAPH. In the absence of AAPH, 0% of entrapped and 
free lutein was degraded over 24 hours, as expected. The percentage of lutein degraded 
after 24 hours in the presence of AAPH was not statistically different for emulsified 
lutein, PLGA (lutein) and PLGA/Chitosan (lutein) due to the amount of lutein released in 
this environment after 24 hours (Figure 3.5).  
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The cholesterol assay based on the measurement of 7-ketocholesterol, the final oxidation 
product of cholesterol oxidation by radicals was used to measure antioxidant activity of 
entrapped lutein. Cholesterol, an unsaturated lipid, undergoes the same three-stage 
oxidation process as unsaturated fatty acids (Laguerre, Lecomte et al. 2007). The double 
bond at carbons 5,6 make cholesterol easier to oxidize than other unsaturated lipids 
(Iuliano 2011). Oxysterols are seen as end products of radical chain reactions with 
cholesterol (Iuliano 2011). The final end product of non-enzymatic cholesterol oxidation 
is 7-ketocholesterol, 3% -hydroxycholest-5-en-7-one, which results from the addition of a 
ketone group to carbon 7 (Iuliano 2011).  
Based on cholesterol oxidation experiments, all PLGA and PLGA/Chitosan nanoparticles 
acted as antioxidants by significantly reducing the oxidation of cholesterol. In order to 
determine whether this occurred via the physical presence of the nanoparticles or via 
chemical reactions of the nanoparticles confocal microscopy was performed. Imaging 
showed that PLGA nanoparticles moved throughout the emulsion independently from the 
emulsion droplets (data not shown) therefore proving that protection from oxidation was 
not simply the result of a NP physical association with the emulsion droplets, but rather 
the chemical composition of the nanoparticle. To further prove this, polystyrene 
nanoparticles were included in the study as a control in the cholesterol experiment. The 
polystyrene nanoparticles did not show any antioxidant activity (Figures 3.6A), clearly 
indicating that the antioxidant properties of PLGA and PLGA/Chitosan nanoparticles 
were associated with chemical activity of the materials making the delivery systems or 
the antioxidant loaded in the nanoparticles. The free carboxylic acid end groups of PLGA 
or the positively charged amine groups of chitosan may have contributed to the 
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antioxidative effects of the NPs through hydrogen donation, explaining the lack of 
antioxidant activity of polystyrene nanoparticles. 
The lutein release (Figure 3.5) coincided with the increased antioxidant activity of lutein 
over time (Figure 3.6B), for antioxidant activity improved as more lutein was released 
over time.  For example, PLGA/Chitosan (lutein) showed 23 % lutein release after 24 
hours and 69%, a much higher release after 72 hours  (Figure 3.5), significantly different 
between all time points. It was therefore inferred that the significant reduction of 
oxidation of cholesterol observed at 48 hours and not at 24 hours was due to the time 
needed for the lutein to be released from the nanoparticle and to reach the interface of the 
emulsion. After 48 hours, lutein, PLGA (lutein), PLGA/Chitosan, PLGA/Chitosan 
(lutein) significantly reduced oxidation of cholesterol compared to the control, and 
PLGA/Chitosan (lutein) significantly reduced oxidation compared to the unentrapped 
lutein control (Figure 3.6B).  
After 72 hours, the treatments of lutein, PLGA, PLGA (lutein), and PLGA/Chitosan 
(lutein) reduced the oxidation of cholesterol compared to the blank, but PLGA/Chitosan 
(lutein) further reduced the oxidation compared to lutein and PLGA(lutein), which is 
explained by the addition of chitosan (Figure 3.6B). Low molecular weight chitosan was 
found to be a scavenger of singlet oxygen and hydroxyl radicals, so the addition of 
chitosan should make a significant difference in antioxidant activity (Xie 2001; Xing, Liu 
et al. 2005; Yen, Yang et al. 2008). 
PLGA/Chitosan (lutein) NPs showed significantly better antioxidant activity than 
PLGA/Chitosan at 72 hours, which is explained by the addition of lutein and the increase 
in lutein release at this time.  
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PLGA (lutein) and PLGA/Chitosan decreased the oxidation of cholesterol compared to 
PLGA, which can be explained by the addition of material with antioxidant properties 





In an effort to determine suitability of polymeric nanoparticles for delivery of 
antioxidants, specifically lutein, the stability and antioxidant activity of lutein entrapped 
in PLGA and PLGA/Chitosan NPs in comparison with unentrapped lutein, were 
measured. Both PLGA and PLGA/Chitosan NPs with entrapped lutein maintained their 
size throughout antioxidant experiments.  PLGA and PLGA/Chitosan NPs did not 
improve the chemical stability of lutein when compared to emulsified lutein in the 
presence of AAPH. However, PLGA/Chitosan NPs improved the antioxidant activity of 
lutein by 21% ± 1% at 48 hours and 21%± 3% at 72 hours compared to emulsified lutein 
using the cholesterol assay (Figure 3.6B). Blank PLGA and PLGA/Chitosan NPs also 
appeared to act as antioxidants in these experiments, whereas polystyrene NPs did not; 
this suggested that blank PLGA and PLGA/Chitosan NPs improved the antioxidant 
activity through chemical reactions rather than providing a physical barrier to oxidation. 
It was concluded that entrapping lutein in PLGA and PLGA/Chitosan NPs did not 
significantly improve lutein stability over that of free lutein, but due to the release of 
lutein over time achieved by entrapping it in PLGA and PLGA/Chi nanoparticles, it 
increased its antioxidant efficacy.  
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The addition of materials of antioxidant activity such as chitosan to the nanoparticles 
further improved the antioxidant activity of the nanoparticle system. 
 
Future Experiments 
The chemical mechanism by which unloaded PLGA and PLGA/Chitosan exhibited 
antioxidant properties is not covered in the published literature. Additional studies 
determining the effect of oxygen concentration and pH of the experimental environments 
on cholesterol oxidation is important for determining the chemical mechanism of action 
by which PLGA and PLGA/Chitosan prevented oxidation of cholesterol. Further 
experiments testing effects of NP properties on antioxidant activity of entrapped lutein 
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CHAPTER 4. CONCLUSIONS  
 
Nanodelivery systems offer many physical and chemical advantages for improved 
functionality of entrapped bioactives; i.e. the addition of chitosan significantly improved 
the antioxidant efficacy of lutein against the oxidation of cholesterol. Each type of 
nanodelivery system offers distinct benefits, and the properties of the bioactive along 
with the purpose of delivery should determine which nanoparticle type is most 
appropriate for the application, i.e. nanodelivery systems for oral delivery should be 
biodegradable and biocompatible. Lutein is one of the few carotenoids found in the retina 
and is essential for diminishing photo-induced oxidative stress in the lens and macula 
lutea in the retina (Alves-Rodrigues and Shao 2004), (Ahmed, Lott et al. 2005). Also in 
the macula lutea of the eye, cholesterol is photooxidized to 7-ketocholesterol and the 
process is linked to macular degeneration (Rodriguez and Larrayoz 2010), (Breuer, 
Dzeletovic et al. 1996). Lutein was proven to significantly reduce the oxidation of 
cholesterol to 7-ketocholesterol, and PLGA/Chitosan (Lutein) was found to improve this 
effect when compared to lutein after 48 hours of oxidation. Further studies should be 
done to determine the nano-bio interaction, bioavailability, and ADME profile of 
PLGA/Chitosan (lutein) compared to free lutein in order to determine if PLGA/Chitosan 
(Lutein) as a nanodelivery system could improve the efficacy of lutein as a treatment for 
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3.1 Lutein Standard Curve: All lutein concentrations were calculated using a lutein 
standard. The absorbance was measured on a UV-Vis spectrophotometer (Genesys 6, 


































Concentration  (micrograms) 
Lutein Standard Curve 
 60 
 3.2 PVA Standard Curve: All NP PVA Concentrations were calculated using a PVA 
standard. The absorbance was measured on a UV-Vis spectrophotometer (Genesys 6, 
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3.3 Size Stability in Cholesterol and Linolenic Acid Emulsions: Size in (nm) and Zeta 
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3.4 Cholesterol Oxidation: 7-ketocholesterol Concentrations 0, 24, 48, and 72 hours and 




Appendix 3.5:  Cholesterol Oxidation from 0 è72 Hours: The general trend of 7-
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3.6 SAS Programs   
 
3.6A: Size Stability 
Title 'Size Stability in Emulsion'; 
Proc Mixed data=work.SIZEE; 
Class NP Beaker Time; 
Model Y = NP|Time / outp= resids; 
Random Beaker(NP) Beaker(NP*Time); 
LSMeans NP|Time / adjust=tukey CL; 
run; 
 
Proc Univariate data = resids plot=normal; 
var resid; 
run; 
PROC IMPORT OUT= WORK.SIZEE  
            DATAFILE= "C:\Users\snavar4\Documents\SAS1\EmulsionSizeStabi 
lity.xlsx"  
            DBMS=EXCEL REPLACE; 
     RANGE="Sheet1$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
RUN; 
3.6 B: Chemical Stability 
Title 'Lutein AND Cholesterol Chemical Stability in Emulsion Experiment'; 
Proc Mixed data=work.RELEASE; 
Class NP Beaker Time; 
Model Y = NP|Time / outp= resids; 
Random Beaker(NP) Beaker(NP*Time); 
LSMeans NP|Time / adjust=tukey CL; 
run; 
 
Proc Univariate DATA = resids plot = normal; 
var resid; 
run; 
PROC IMPORT OUT= WORK.Release  
            DATAFILE= "C:\Users\tborel1\Documents\RELEASE.xlsx"  
            DBMS=EXCEL REPLACE; 
     RANGE="Sheet4$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
RUN; 
 
dm 'log; clear; output; clear'; 
options nodate; 
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3.6 C: Cholesterol Oxidation 
 
dm 'log; clear; output; clear'; 
options nodate; 
 




Proc Mixed data=WORK.SASCHOL3; 
Class REP TREATMENT BEAKER TIME; 
Model POSTY = TREATMENT TIME (TREATMENT*TIME)/ output=resids; 
Random REP(TREATMENT) BEAKER(TREATMENT) REP(TREATMENT*TIME)  
BEAKER(REP*TREATMENT*TIME); 
LSMeans TREATMENT TIME (TREATMENT*TIME)/ adjust=tukey CL; 
run; 
 






PROC IMPORT OUT= WORK.SASCHOL3  
            DATAFILE= "C:\Users\snavar4\Documents\SAS1\SASCD2.xlsx"  
            DBMS=EXCEL REPLACE; 
     RANGE="Sheet1$";  
     GETNAMES=YES; 
     MIXED=NO; 
     SCANTEXT=YES; 
     USEDATE=YES; 
     SCANTIME=YES; 
RUN; 
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